• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Janux Therapeutics Inc (NQ: JANX )

    38.50 UNCHANGED
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 38.50
    Bid (Size) 36.35 (1)
    Ask (Size) 44.65 (1)
    Prev. Close 38.50
    Today's Range 38.50 - 38.50
    52wk Range 5.650 - 65.60
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
    Although fraught with risk, these biotech exposures bring enormous upside potential. 
    Via Talk Markets
    Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
    Via Benzinga

    Performance

    YTD
    +249.36%
    +249.36%
    1 Month
    -20.65%
    -20.65%
    3 Month
    +8.76%
    +8.76%
    6 Month
    +267.02%
    +267.02%
    1 Year
    +216.87%
    +216.87%

    More News

    Read More
    The Latest Analyst Ratings For Janux Therapeutics
    Via Benzinga
    Analyst Ratings For Janux Therapeutics
    Via Benzinga
    JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
    Via Benzinga
    Why Janux Therapeutics Stock Is Crushing It This Week
    Via The Motley Fool
    Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
    Via Benzinga
    Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Take the Money and Run: 3 Overbought Stocks to Sell ASAP
    Via InvestorPlace
    These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
    Via InvestorPlace
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
    Via Benzinga
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Via Investor's Business Daily
    Why Janux Therapeutics Stock Soared as the Market Sagged Today
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
    Via Benzinga
    JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    2 Stocks That Have More Than Tripled This Year: Are They Buys?
    Via The Motley Fool
    B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
    Via Benzinga
    Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    5 Stocks That More Than Doubled In February
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.